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ABSTRACT: Macrophages, one of the most important phagocytic cells of the immune system, are highly plastic and are known
to exhibit diverse roles under diﬀerent pathological conditions.
The ability to repolarize macrophages from pro-inﬂammatory
(M1) to anti-inﬂammatory (M2) or vice versa oﬀers a promising
therapeutic approach for treating various diseases such as traumatic
injury and cancer. Herein, it is demonstrated that macrophageengineered vesicles (MEVs) generated by disruption of macrophage cellular membranes can be used as nanocarriers capable of
reprogramming macrophages and microglia toward either pro- or
anti-inﬂammatory phenotypes. MEVs can be produced at high yields and easily loaded with diagnostic molecules or
chemotherapeutics and delivered to both macrophages and cancer cells in vitro and in vivo. Overall, MEVs show promise as
potential delivery vehicles for both therapeutics and their ability to controllably modulate macrophage/microglia inﬂammatory
phenotypes.

■

INTRODUCTION
Macrophages are an essential component of the innate
immune system where they play a diverse role. Macrophage
function includes clearing waste materials such as cellular
debris and participating in tissue repair and remodeling that
occurs during wound healing.1 They also serve as a defense
against bacterial infections and other pathogens largely through
phagocytosis.2,3 Additionally, they are integral to the initiation
of an adaptive immune response through their antigen
presenting capabilities.4 As a result of this versatile role,
macrophages exhibit a range of functional activities which are
often driven by stimuli in the surrounding environment.5
Macrophages exist in a continuum of polarization states
between a pro-inﬂammatory phenotype, classiﬁed as M1, and
an anti-inﬂammatory phenotype, classiﬁed as M2.6 The
polarization state is often mediated by environmental signals
such as cytokines, fatty acids, and components from microorganisms such as lipopolysaccharides (LPSs).7,8 Pro-inﬂammatory macrophages are characterized by the production of
nitric oxide and the release of high levels of inﬂammatory
cytokines including IL-12, TNF-α, and IL-1β.1 Anti-inﬂammatory macrophages secrete cytokines which can dampen the
immune response such as IL-10 and IL-4.9
The expression of speciﬁc macrophage cytokines is
implicated in the progression of several disease states. For
example, recent studies have shown that macrophages are
involved in the progression of cancer, inﬂammatory diseases,
and infectious diseases.10 In the tumor microenvironment,
© 2021 The Authors. Published by
American Chemical Society

macrophages exhibit an anti-inﬂammatory phenotype and are
known as alternatively activated or tumor-associated macrophages (TAMs).11 While IFN-γ and IL-12 release by proinﬂammatory macrophages have an anti-angiogenic eﬀect and
can block the formation of the new blood vessels in the tumor
microenvironment, TAMs suppress production of these
cytokines.12−16 Factors released by cancer cells in the tumor
microenvironment cause TAMs to become tumor-supportive
assisting in growth, tissue remodeling, angiogenesis, and
metastasis.13,17 Tumor progression is further supported by
TAMs which produce reduced levels of the major histocompatibility complex (MHC)-II which suppresses the antitumor adaptive immune response.18,19 Macrophages also play a
critical role in the inﬂammatory response such as during spinal
cord injury (SCI).20 As the blood−brain barrier is compromised following SCI, peripheral macrophages rapidly invade
the spinal cord and contribute to both pathological and
reparative processes.21 While pro-inﬂammatory macrophages
contribute to neurodegeneration and tissue loss after SCI, antiinﬂammatory macrophages contribute to tissue remodeling
and axon regeneration.22−24 Control of macrophage phenotype
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Scheme 1. Schematic Illustrating the Approach of Generating Vesicles from Polarized Bone Marrow-Derived Macrophagesa

a
Fully diﬀerentiated unstimulated macrophages (M0) are polarized into either pro-inﬂammatory macrophages (M1) or anti-inﬂammatory
macrophages (M2). Nitrogen cavitation is then used to fragment the cellular membranes of these cells generating M1-engineered vesicles (M1EVs)
or M2-engineered vesicles (M2EVs). Vesicles are then separated from cellular fragments by serial centrifugation. These vesicles are then delivered
to either unstimulated or polarized macrophages to shift the polarization toward the polarization type of the MEVs.

Figure 1. MEV characterization. (A) Fluorescence image of MEVs loaded with a ﬂuorescent dye (ﬂuorescein) during vesicle generation illustrating
the principle of encapsulation of cargo by MEVs. (B) Fluorescence image of MEVs labeled with the lipophilic dye, DiI. (C) Size distribution of proinﬂammatory MEVs (M1EVs) measured by nanoparticle tracking analysis. (D) Size distribution of anti-inﬂammatory MEVs (M2EVs). The
eﬀective diameter of the vesicles generated by nitrogen cavitation was between 100−200 nm. (E) Eﬀective diameter of M1 vesicles in PBS for 3
days measured using dynamic light scattering. (F) 3D confocal image of an M2 macrophage after delivery of ﬂuorescein (interior)-loaded M1EVs
labeled with DiI (lipid bilayer), showing clear uptake of vesicles on the surface and inside by macrophages.

macrophages and dendritic cells possess the ability to
repolarize TAMs to pro-inﬂammatory macrophages in the
tumor microenvironment.30−32 Despite their promise in
shifting macrophage phenotype as a therapeutic approach,
EEV-based therapies are still challenged by low production
yields and diﬃculties in separating target vesicles from other
similarly sized vesicles.33 Vesicles artiﬁcially generated from
cellular membranes have been found to mimic many of the
properties of EEVs.28,33−38 For example, recent studies
demonstrated that vesicles derived from cellular membranes
of RAW264.7 cells can stimulate anti-inﬂammatory macrophages toward a pro-inﬂammatory phenotype. Studies have
also shown that cell-derived vesicles from tumor cells exhibit
targeted delivery back to the cell of origin.36
In the present study, we generated vesicles from mouse bone
marrow-derived macrophages (BMDMs) and demonstrate that
we can tune their capability to repolarize macrophages toward

through the ability to shift therapeutically between proinﬂammatory and anti-inﬂammatory polarizations has been
proposed as a potential treatment for diseases such as some
types of cancer and traumatic injury.25,26 Under diﬀerent
pathological conditions, macrophages exhibit heterogeneity
across a continuum of polarization states. The ability to
repolarize macrophages from one phenotype to another is a
promising technique which might enable alternative forms of
treatment for several diseases. For example, repolarizing TAMs
toward a pro-inﬂammatory phenotype is an attractive means to
sensitize cancer to immunotherapy.27,28 Similarly, repolarizing
pro-inﬂammatory macrophages toward anti-inﬂammatory
phenotypes, thereby reducing the potential neurotoxic eﬀects
of M1 macrophages, could be a promising approach for
treating SCI and stroke.9,24,29
Studies have shown that endogenous extracellular vesicles
(EEVs) such as exosomes obtained from immune cells such as
3848
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Figure 2. Macrophage targeting speciﬁcity. (A−D) Wideﬁeld ﬂuorescence images of M2 macrophages showing the time-dependent uptake of DiIlabeled M1EVs by M2 macrophages, scale bar = 30 μm. (E) Comparison of M1EVs delivered to M1 macrophages (black) vs M1EVs delivered to
M2 macrophages (red). (F) Comparison of M2EVs delivered to M1 macrophages (black) vs M2EVs delivered to M2 macrophages (red). (G)
Comparison of M2 Macrophages with M1EV delivery (green), M2 macrophages incubated with dynasore (80 μM) for 30 min prior to M1EV
addition (gold), and M2 macrophages with M1EV delivery in the presence of DMSO (delivery vehicle) (red). Each data point is the average of ﬁve
independent replicates (n = 5). Norm. ID is the mean integrated density of the image normalized to the mean integrated density value of M2
macrophages before adding vesicles. The data are presented as the mean ± SEM. **p < 0.01 indicates a signiﬁcant diﬀerence in the vesicle uptake
by macrophages at respective time points.

distribution of vesicles and their concentration. Particle
tracking (Nanosight 300) determines particle size based on
diﬀusion rates and the concentration by counting the number
of particles in a deﬁned volume. Vesicles generated from
approximately 100 million M1 BMDMs in culture using
nitrogen cavitation yielded 5.5 × 1010 vesicles (M1EVs).
Similarly, 100 million M2 macrophages yielded 6.9 × 1010
vesicles (M2EVs). The size distribution of MEVs generated by
nitrogen cavitation at 300 psi is primarily between 100−200
nm, which is similar to that of exosomes.39,40 The mean
diameter of M1EVs was found to be 144.6 nm (Figure 1C)
and that of M2EVs was found to be 137.8 nm (Figure 1D). We
further measured the zeta potential of MEVs suspended in the
PBS buﬀer and found that M1EVs had a zeta potential value of
−104 ± 2 mV and M2EVs had a zeta potential of −84 ± 2 mV.
A large negative value for the zeta potential indicates the
stability of MEVs in aqueous solution.33,41−43 These initial
characterization studies show that vesicles from BMDMs can
be generated with a similar size to exosomes. Additionally, we
were able to produce a large number of vesicles from a
relatively small volume of tissue culture without the need to
wait for long periods of time for the production of EEVs
through normal physiological processes.
We next tested the stability of MEVs over time to determine
their potential suitability as a drug delivery vehicle where they
would be required to circulate within the human body for a
period of time before delivery of cargo to a speciﬁc site. We
tested the stability of MEVs generated by nitrogen cavitation
by incubating them in solution for 3 consecutive days. We
monitored vesicle size over time to determine the extent of
aggregation. The size of MEVs remained relatively constant for
the ﬁrst 2 days, signifying the stability of MEVs over this
interval. After 48 h, the stability gradually decreased, as shown
by the increase in the size of the vesicles (Figure 1E). Thus, in

either pro- or anti-inﬂammatory phenotypes. We also
characterized these macrophage-engineered vesicles (MEVs)
to show that they are similar in size to EEVs and exhibit cell
targeting capability for delivery of therapeutics to both cancer
cells and macrophages.

■

RESULTS AND DISCUSSION
Characterization of MEVs. MEVs are generated through
mechanical disruption of the cell membrane into nano-sized
fragments which reform into vesicles. Here, we used a
prechilled nitrogen decompressor and maintained BMDMs at
a pressure of 300 psi for at least 5 min. The sudden release of
pressure causes the cell membrane to fragment, and because
the phospholipids composing the membrane are amphipathic,
the hydrophobic eﬀect drives these fragments to spontaneously
form vesicles in aqueous solutions. These vesicles are separated
from cellular debris by a series of centrifugation and
ultracentrifugation steps as depicted in Scheme 1. Vesicles
are generated in the presence of the solution in which the cells
were initially suspended, leading to the encapsulation of any
hydrophilic therapeutic or other cargo present in the aqueous
solution during vesicle generation. Figure 1A shows a
ﬂuorescence image of MEVs generated by nitrogen cavitation
in the presence of a ﬂuorescein-containing solution.
Fluorescein is a ﬂuorescent dye that is soluble in an aqueous
medium and is entrapped within the vesicles during their
formation. Green punctate regions in the ﬂuorescence image
indicate the presence of ﬂuorescein inside the vesicles and the
successful loading of cargo during vesicle generation. Similarly,
MEVs can be labeled with a lipophilic dye such as DiI. The
ﬂuorescence image in Figure 1B shows red punctate regions
corresponding to DiI incorporation into the vesicle membrane.
To determine the yield of MEVs during nitrogen cavitation,
we performed multiple particle tracking to extract both the size
3849
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Figure 3. Reprogramming macrophage polarization with MEVs. (A) Measurement of the pro-inﬂammatory cytokines and nitric oxide (NO)
released by M0, M1, and M2 macrophages compared to the production of cytokines released after M1EV delivery to M2 and M0 macrophages.
Both M0 and M2 macrophages are polarized toward an M1 phenotype upon interaction with M1EVs in vitro. (B) Quantiﬁcation of proinﬂammatory cytokines and NO expression by M0 and M1 macrophages when incubated with M2EVs for 24 h in vitro. Pro-inﬂammatory cytokines
released by M1 macrophages are signiﬁcantly reduced upon interaction with M2EVs, which shows that M2EVs are capable of reprogramming M1
macrophages toward an M2 phenotype. Each data point is the average of at least three experiments (n = 3). The data are presented as the mean ±
SEM.

both M1EVs and M2EVs compared to M1 macrophages
(Figure 3E,F).
Dynamin activity is an integral component of both
endocytosis and phagocytosis.44,45 Dynasore, a dynamin
inhibitor, has been widely used to study the process of
internalization of exosomes from the surface of the macrophage.44,46,47 Recent studies showed that the knockdown of
dynamin 2 almost completely inhibited the uptake of exosomes
by RAW264.7 macrophage-like cells.48 Since MEVs mimic
exosomes, we next investigated whether they exhibited a
similar mechanism of vesicle internalization by macrophages.
We compared the uptake of ﬂuorescently labeled M1EVs by
M2 BMDMs in the presence and absence of dynasore.
Dynasore (80 μM) was added to cultured macrophages 20 min
prior to the addition of labeled vesicles. M2 macrophages were
left to incubate with M1EVs for 2 h and subsequently imaged
by wide-ﬁeld microscopy. We found that dynasore had no
eﬀect on the cell viability and macrophages looked
morphologically similar with and without treatment. We
calculated the integrated density of the ﬂuorescence signal to
compare the uptake of M1EVs by M2 macrophages. We found
that dynasore resulted in 64% reduction in uptake of vesicles
relative to the control (Figure 2G). We performed similar
vesicle uptake control experiments in the presence of the
vehicle, DMSO, at an equal concentration. We found that
there was no signiﬁcant eﬀect of DMSO on the M1EV uptake
process by M2 macrophages relative to the control with no
DMSO or dynasore. Macrophages are well-established
phagocytotic cells. The loss of cellular uptake with dynamin
inhibition coupled with the observation of intact vesicles inside
macrophages indicates that macrophages are likely internalizing vesicles via phagocytosis. These results demonstrate that
MEVs exhibit similar properties to exosomes and are able to
target macrophages.
MEVs Reprogram Macrophage Phenotypes. Previous
studies have shown that exosomes generated from M1 or M2
macrophages can be used to diﬀerentiate naive macrophages
into the corresponding pro- or anti-inﬂammatory phenotypes.30,49 After conﬁrming that MEVs can be delivered to

addition to their high yields, MEVs are also stable for times
compatible with the likely circulation time needed for
therapeutic delivery.
MEV Delivery to Macrophages. Previous studies have
shown that vesicles generated from cellular membranes can be
used as eﬃcient therapeutic delivery vehicles to deliver cargo
to the interior of the cell.36 In order to investigate the ability of
MEVs to deliver cargo into the interior of macrophages, we
ﬁrst generated MEVs from BMDMs stimulated to be M1
(INF-γ + LPS) and loaded with ﬂuorescein. The M1EVs were
labeled concomitantly with the lipophilic dialkylcarbocyanine
ﬂuorescent dye, DiI, which embeds into the lipid bilayer of the
vesicles. Both ﬂuorescent labels were separated from the
unloaded dye using a size exclusion column. We then
incubated BMDMs stimulated with IL-4, to generate M2
cells, with the M1EVs. After incubation with these M2
macrophages, we observed bright ﬂuorescence after 2 h when
imaged with confocal microscopy under both 488 nm
(ﬂuorescein) and 532 nm (DiI) excitation (Figure S1).
M1EVs were evident inside of M2 macrophages, as shown
from the ﬂuorescence puncta both inside and on the
membrane of macrophages (Figure 1F). At 2 h after
incubation, most vesicles remain intact and isolated on the
membrane as well as inside of the cell.
After conﬁrming the delivery of M1EVs onto M2 macrophages, we next performed a set of experiments to determine if
vesicles generated from M1 and M2 BMDMs possess diﬀerent
macrophage targeting capabilities. We generated DiI-labeled
vesicles from an equal number of M1 or M2 macrophages. We
then determined the eﬃciency of delivery to M1 and M2
macrophages by measuring the ﬂuorescence signal at various
time points over 2 h. We added M1EVs and M2EVs separately
to M1 or M2-stimulated BMDMs. Vesicles were then rinsed
from the cells, and the cells were subsequently imaged using
wide-ﬁeld microscopy. We found time-dependent uptake of
MEVs by macrophages (Figure 2A−D). While both M1EVs
and M2EVs were eﬃciently delivered to M1 and M2
macrophages, M2 macrophages showed a higher uptake of
3850
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most of the pro-inﬂammatory cytokines, indicating that
M2EVs do not induce most of the pro-inﬂammatory properties
in target M0 macrophages (Figure 3B). This indicates that the
delivery of vesicles themselves does not simply generate a proinﬂammatory response that was seen only with M1EV delivery.
We further compared the cytokine production from M1
macrophages, M2 macrophages, and M1 macrophages
incubated with M2EVs. We observed clear pro-inﬂammatory
markers from M1-macrophages but virtually no levels for most
of the pro-inﬂammatory cytokines in the M2 culture. We
further observed a clear decrease in the levels of all the proinﬂammatory markers for M1 macrophages that were
incubated with M2EVs (Figure 3B). M2EVs signiﬁcantly
attenuated cytokine released by M1 macrophages by 99%
(IFN-γ), 85% (IL-10), 74% (IL-12p70), 9% (IL-1β), 72% (IL6), 78% (KC/GRO), and 96% (TNF-α) of the average
concentration seen for M1 macrophages (Figures 3B and S5).
We also observed a signiﬁcant reduction (49%) in NO
production by M1 macrophages that were incubated with
M2EVs compared to the average concentration seen for M1
macrophages. This indicates that M2EVs can reprogram M1
macrophages away from a pro-inﬂammatory phenotype. This
has important implications on the use of MEVs to reprogram
macrophage phenotype as part of a therapeutic approach. The
phenotype used to generate MEVs appears to dictate their
ability to reprogram both naive and already polarized
macrophages toward a desired phenotype. The ability to
alter macrophage inﬂammatory properties could be an
important therapeutic tool to reprogram anti-inﬂammatory
macrophages to a pro-inﬂammatory phenotype.
Repolarization of Microglia. Microglia are immune cells
present in the central nervous system.50 Similar to macrophages, microglia are also polarized to M1 and M2 phenotypes
and play pro- and anti-inﬂammatory roles, respectively.51 To
determine if macrophage-derived vesicles are able to reprogram microglia phenotypes, we delivered vesicles derived from
macrophages to primary microglia cells in culture. We induced
M2 microglia polarization using IL-4. M1EVs generated from
bone marrow-derived M1 (LPS + INF-γ) macrophages were
then added to cultured M2 microglia to compare the cytokine
production from M1 microglia, M2 microglia, and M2
microglia incubated with M1EVs. We observed clear proinﬂammatory markers from M1 microglia and virtually no
measurable levels for most of the cytokines in the M2 microglia
culture. We also observed an increase in the levels of all the
pro-inﬂammatory markers for M2 microglia that were
incubated with M1EVs (Figure S6). The ability of M1EVs to
reprogram M2-polarized microglia toward a pro-inﬂammatory
(M1) phenotype in a controlled fashion suggests that we can
reprogram both macrophage and microglia inﬂammatory
properties by the delivery of vesicles that are targeted to
speciﬁc cell types. Furthermore, similar to macrophage
exosomes, MEVs can deliver the corresponding signals to
unstimulated macrophages and diﬀerentiate them into speciﬁc
phenotypes. This has implications for therapeutic approaches
where the goal is to either initiate or suppress a proinﬂammatory response.
The ability of MEVs to reprogram immune cells is likely due
to membrane-bound proteins on the surface of the vesicle. As
they are derived from parent immune cells, MEVs carry a wide
range of transmembrane proteins, membrane-bound cytokines,
and other cell signaling endogenous ligands. These proteins

macrophages, we tested their ability to diﬀerentiate naive (M0)
macrophages. M1EVs were generated using nitrogen cavitation
from cultured M1 macrophages and then delivered to M0
macrophages to compare cytokine production from M0
macrophages, M1 macrophages, and M0 macrophages
incubated with M1EVs. Macrophage-conditioned media
(MCM) were extracted from the cell culture of each sample.
We performed a meso-scale delivery Sevenplex ELISA that
simultaneously tested for seven mouse pro-inﬂammatory
cytokines (IFN-γ, IL-10, IL-12p70, IL-1β, IL-6, KC/GRO,
and TNF-α) in the cell culture supernatant. We observed clear
pro-inﬂammatory markers from M1 macrophages and virtually
no measurable levels for most of the cytokines in the M0
culture (Figure 3A). We also found that M1EVs can reprogram
M0 macrophages toward an M1 phenotype as evidenced by
the increased production of each of the pro-inﬂammatory
cytokines (n = 3/group) from undetectable to 6 ± 6% (IFNγ), 45 ± 2% (IL-10), 29 ± 1% (IL-12p70), 81 ± 63% (IL-1β),
12 ± 5% (IL-6), 36 ± 13% (KC/GRO), and 20 ± 8% (TNFα) of the average concentration seen for M1 macrophages
(Figures 3A and S2). These results veriﬁed that M1EVs can
stimulate M0 BMDMs toward a pro-inﬂammatory phenotype.
We did not observe a shift toward a pro-inﬂammatory
phenotype when M2MEVs were added to M0 macrophages.
Our results reinforce the claim that MEVs exhibit similar
properties to exosomes and can be used to polarize naive
macrophages.
We next performed a set of experiments to determine the
eﬀect of vesicle delivery on macrophages that have already
been polarized toward a speciﬁc phenotype. We examined the
ability of pro-inﬂammatory vesicles to inﬂuence anti-inﬂammatory macrophages as well as the ability of anti-inﬂammatory
vesicles to inﬂuence pro-inﬂammatory macrophages. To test
the capability of MEVs to reprogram already polarized
macrophages, we treated cultured M2 BMDMs with M1EVs
and compared the cytokine production from M1 macrophages,
M2 macrophages, and M2 macrophages exposed to M1EVs.
For M2 macrophages that had been treated with M1EVs, we
found a signiﬁcant increase in the production of cytokines (n =
3/group) from undetectable to 10 ± 1% (IFN-γ), 91 ± 20%
(IL-10), 37 ± 12% (IL-12p70), 77 ± 30% (IL-1β), 44 ± 20%
(IL-6), 85 ± 27% (KC/GRO), and 55 ± 18% (TNF-α) of the
average concentration seen for M1 macrophages (Figures 3A
and S3). We further performed a Griess assay to assess the
nitric oxide (NO) presence in MCM collected from M1, M2,
and M2 macrophages that were incubated with M1EVs. We
found a signiﬁcant increase in the production of nitric oxide
from negligible initial amounts in M2 to 41 ± 0.4% of the
average concentration seen for M1 macrophages when M2
macrophages were treated with M1EVs. Comparing M2 versus
M0 macrophages treated with M1EVs, M1EVs were able to
induce a greater increase in pro-inﬂammatory indicators in M2
macrophages. Control studies showed that MEVs themselves
only have marginal amounts of cytokines and they would not
be responsible for the amounts seen after the shift (Figure S4).
These results indicate that M1EVs can repolarize M2 BMDMs
toward a pro-inﬂammatory M1 phenotype as evidenced by the
increase in inﬂammatory cytokine production.
We also added M2 vesicles to cultured M0 macrophages and
compared the cytokine production from M1 macrophages, M0
macrophages, and M0 macrophages incubated with M2EVs
(Figure 3B). We found that upon incubation of M0
macrophages with M2EVs, M0 macrophages did not produce
3851
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can interact with membrane receptors on the target cell
initiating signaling cascades that lead to repolarization.
Macrophage-Induced Neurotoxicity. Classically activated M1 macrophages, stimulated with LPS + IFN-γ, are
neurotoxic and contribute to neuronal degeneration by
releasing high levels of speciﬁc pro-inﬂammatory cytokines
and oxidative metabolites such as nitric oxides.9,52 Proinﬂammatory cytokines such as TNF-α, IFN-γ, IL-12, and
IL-6 have been found to be involved in neuronal death.53−55
Alternatively activated, M2 macrophages do not induce cell
death but rather help the repair process by releasing growth
factors and anti-inﬂammatory cytokines.22,23 Recent studies
showed that azithromycin (AZM), a frequently used macrolide
antibiotic, also possesses the ability to reduce macrophagemediated neurotoxicity by altering macrophage phenotype
from pro-inﬂammatory to anti-inﬂammatory.9,56 We sought to
determine if MEV-induced reprogramming of M1 macrophages toward an M2 phenotype could moderate neurotoxicity
in a similar fashion to AZM.9 We used LPS + IFN-γ to
stimulate an M1 macrophage phenotype and IL-4 to stimulate
an M2 phenotype. We generated vesicles from M2 macrophages and then exposed M1 macrophages to M2 MEVs,
which reduces the production of pro-inﬂammatory cytokines
(Figure 3B). We collected the supernatant from M1 macrophages and M1 macrophages that had been exposed to M2EVs
for 24 h. Media from both conditions were used to separately
treat diﬀerentiated Neuro-2A (N2a) cells. N2a cells are a
mouse neural crest-derived cell line which possess the ability to
diﬀerentiate into cells with neuron-like characteristics. We
found that media from M1 macrophages resulted in a 40%
reduction in neuron viability relative to the control media
(Figure 4A) (n = 5/group). We further found that media
collected from M1 macrophages that had been exposed to
M2EVs for 24 h resulted in no signiﬁcant reduction in neuron
viability relative to the control (Figure 4A). This is likely due
to the signiﬁcant reduction of pro-inﬂammatory cytokines by
M1 macrophages upon incubation with M2EVs (comparable
to AZM-treated M1 cells, Figure 4B), and the corresponding

Article

increase in neuron viability suggests that pro-inﬂammatory
cytokines released by M1 macrophages play a major role in the
cytotoxicity of N2a cells. These results also indicate that
reprogramming M1 macrophages toward an anti-inﬂammatory
phenotype using M2EVs is comparable to an immunomodulatory pharmacological agent and reduces the cytotoxicity
normally observed with pro-inﬂammatory macrophages.
MEVs for Therapeutic Delivery. Previous studies have
shown that vesicles generated from A549 (lung carcinoma)
cells can target as well as deliver chemotherapeutics to the
same cell type from which they were generated.36 There is
some concern about the use of cancer cell-derived vesicles for
drug delivery because of the potential for these vesicles to be
cleared by the body’s immune system and that these vesicles
might increase the metastatic potential. We tested MEVs to
determine if they had similar targeting and therapeutic delivery
features as were previously observed for cancer cell vesicles.
MEVs lack any cancer characteristics and would not increase
the metastatic potential. We ﬁrst performed an experiment to
determine the targeting ability of MEVs for A549 cells. We
generated vesicles from macrophages and labeled them with
DiI. We then determined the eﬃciency of delivery of MEVs by
measuring the ﬂuorescence signal at time points over 4 h. We
observed an increase in the ﬂuorescence intensity over time
resulting from an uptake of MEVs by the A549 cells. The
uptake of MEVs by A549 cells suggests that MEVs can serve as
a potential drug delivery vehicle in the delivery of chemotherapeutics (Figure S7). We next determined if MEVs could
be loaded with cisplatin and delivered to cancer cells while
maintaining the eﬃcacy of the therapeutic. We also compared
the speciﬁcity of cisplatin delivery onto A549 cells using
M0EVs, M1EVs, and M2EVs (Figure 5A). We found that

Figure 5. MEVs as biological nanocarriers. (A) Comparison of
targeting speciﬁcity of cisplatin-loaded M0, M1, and M2-engineered
vesicles to A549 cells. Each data point is the average of ﬁve
independent replicates (n = 5). ANOVA with post hoc Tukey’s HSD
was used to test the signiﬁcance of the results. **p < 0.01 indicates
that the results are statistically signiﬁcant. The data are presented as
the mean ± SEM. (B) Mice bearing A549 xenografts were injected
with DiR labelled M1EVs, demonstrating that M1EVs can reach the
tumor of the mice.

Figure 4. Macrophage-mediated neurotoxicity. (A) The eﬀect of
macrophage-conditioned media on the viability of diﬀerentiated N2a
cells was determined using a cell viability assay for control cells with
growth media (pink), for the supernatant from M1 macrophage
culture (green), and for the supernatant from M1 macrophage culture
after treatment with M2EVs (blue). (B) Comparative study of the
ability of M2EVs and AZM in solution (10 μM) to reprogram M1
macrophages toward an M2 phenotype. Each data point is the average
of ﬁve independent replicates (n = 5). **p < 0.01 indicates that the
results are statistically signiﬁcant. The data are presented as the mean
± SEM.

empty M0EVs and M2EVs had no signiﬁcant eﬀect on A549
cell proliferation. However, M1EVs resulted in 10% A549 cell
death in 24 h. We further generated cisplatin-loaded M0EVs
(Cs-M0EVs), M1EVs (Cs-M1EVs), and M2EVs (Cs-M2EVs)
from an equal number of M0, M1, and M2 macrophages.
Previous studies have shown that vesicles generated using
nitrogen cavitation can eﬃciently encapsulate chemotherapeutics and are stable for 2 days.36 Therapeutic-loaded MEVs were
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bovine serum (FBS), 1% penicillin/streptomycin (PS), 1% (4(2-hydroxyethyl)-1-piperazineethanesulfonic acid), 0.001% βmercaptoethanol, 1% glutamine, and 20% supernatant from
sL929 cells) and plated in T-175 cell culture ﬂasks in
diﬀerentiation media. sL929 cell lines were maintained in
RPMI media supplemented with 10% FBS, 1% PS, and 1%
glutamine. The supernatant from sL929 cells contains the
macrophage-colony stimulating factor (MCSF), which is
essential for diﬀerentiating bone marrow cells into macrophages. Diﬀerentiation media were replaced on days 2, 4, and
6, and the cells were replated on day 7 at a cell density of 1 ×
106 cells/mL in replating media [Dulbecco’s modiﬁed Eagle’s
medium (DMEM) supplemented with 10% FBS, 1%
glutamine, and 1% PS). On day 8, cells were stimulated to
M1 [LPS (20 ng/mL; Invivogen) + IFN-γ (20 ng/mL;
eBioscience)] or M2 [IL-4 (20 ng/mL); eBioscience]
macrophages, while the unstimulated macrophages from day
7 were termed M0 macrophages. For cytokine analysis, the
supernatant from stimulated cells, MCM, was collected after 24
h. Vesicles were added after 12 h of stimulation, and the
supernatant was collected after 24 h of vesicle addition to M1
or M2 macrophages. The MCM obtained were collected into
Eppendorf tubes and stored at −80 °C until the analysis was
done.
Primary cultures of microglia were prepared from postnatal
P2 to P4 pups from C57BL/6 mice. Brieﬂy, pups were
decapitated, and brains were kept in Petri dishes ﬁlled with icecold Hank’s Balanced Salt Solution (Ca2+, Mg2+, NaHCO3,
and phenol red). Brains were dissected, and the hippocampal
region was extracted for microglia isolation and culture. The
tissues were then minced, and the cell suspension was made.
The cell suspension was treated with 2.5% trypsin (quality
biological), incubated, and ﬁnally resuspended in the astrocyte
culture media containing DMEM with 10% FBS and 1% PS.
Cells were incubated at a density of 2 million on a poly-Llysine-coated T75 ﬂask containing astrocyte culture media.
Cell culture media were changed every 3 days until the ﬂask
was conﬂuent with cells. Microglia were detached from
astrocytes and oligodendrocytes by shaking the ﬂasks for 30
min at a speed of 180 rpm.
The mouse neuroblastoma cell line (also known as Neuro-2a
or N2a) was maintained in the N2a cell culture medium
composed of 44% DMEM, 45% OPTI−MEM reduced-serum
medium, 10% FBS, and 1% PS. A total of 40,000 N2a cells
were plated in each well of a 96-well plate in N2a media
supplemented with 20 μM retinoic acid (Sigma-Aldrich) and
allowed to diﬀerentiate for 24 h. Retinoic acid helped N2a cells
to diﬀerentiate into cells with neuron-like properties.58 On day
1, the diﬀerentiation media were exchanged for 100 μL of
various MCM in 20 μM retinoic acid and two controls with
and without 20 μM retinoic acid. Cells were further incubated
for 48 h, and the neurotoxicity of MCM was evaluated using an
alamar blue cell proliferation assay.
Human lung cancer (A549) cells were maintained in the
A549 cell culture medium composed of 89% DMEM, 10%
FBS, and 1% PS. A total of 40,000 A549 cells were plated in
each well of a 96-well plate and left to incubate for 12 h at 37
°C. After 12 h, the old growth media were removed carefully,
being sure not to disturb the cells, and were exchanged with
A549 cell media containing cisplatin-loaded macrophage (M0,
M1, and M2)-engineered vesicles or empty (M0, M1, and M2)
vesicles. After 24 h of incubation at 37 °C, the media were

then delivered to cancer cells to determine cytotoxicity.
Cisplatin-loaded M0 and M2 vesicles resulted in 45 and 40%
cell death, respectively, at 24 h. However, cisplatin-loaded M1
vesicles resulted in a 60% A549 cell death in 24 h (Figure 5A).
This is a clear indication that cisplatin-loaded M1 MEVs are
more eﬃcient in killing cancer cells compared to cisplatinloaded M0 and cisplatin-loaded M2 macrophages.
In Vivo Delivery of MEVs to Tumor Xenografts. To
determine if MEVs exhibited similar targeting features in vivo
as observed in cell culture, we generated vesicles from M1
macrophages and labeled them with a membrane dye, DiR.
The free dye was separated from MEVs using PD Miniprep
columns. We found that M1EVs targeted tumor xenografts
(subcutaneous injection A549 cells) implanted in immunecompromised athymic nude (nu/nu) mice. After the tumor
xenograft reached at least 100 mm3, we injected 2 × 1010
vesicles through the tail vein of each of the three diﬀerent mice.
We used an IVIS whole animal imager for in vivo imaging.
Imaging was done at 48 and 72 h post injection of labeled
vesicles. DiR alone when injected into the mice as a control
showed nonspeciﬁc accumulation. We observed clear delivery
of the labeled vesicles to the tumor xenograft at 72 h post
injection of labeled vesicles (Figure 5B). These results verify
that M1EVs can speciﬁcally target the tumor tissue in vivo.

■

CONCLUSIONS
In conclusion, BMDMs can be used to engineer nano-sized
vesicles with high yield using nitrogen cavitation. These
vesicles can be loaded with various cargo during their
generation and can be used as drug delivery vehicles both in
vitro and in vivo. In addition, MEVs when interacting with the
macrophage itself possess the ability to reprogram macrophages and microglia into speciﬁc inﬂammatory phenotypes
that dictate the macrophage function (e.g., neurotoxicity and
tumor migration). This shows the potential for MEVs as a
novel and versatile therapeutic to target and reprogram
macrophages.

■

EXPERIMENTAL SECTION
Animals. We used 2−5-month-old wild-type C57BL/6
mice to extract bone marrow cells. Animals were properly
accommodated in IVC cages by providing enough food and
water. All experiments were performed following the guidelines
of the National Institute of Health and were approved by the
Institutional Animal Care and Use Committee at the
University of Kentucky.
Cell Culture. BMDMs were isolated from both tibias and
femurs of wild-type mice at 2−5 months of age as previously
reported.23,57 Brieﬂy, mice were ﬁrst anesthetized and then
killed by cervical dislocation. After removing femurs and tibias
from the carcass, the bone marrow was extracted using a 10
mL syringe loaded with Roswell Park i Institute (RPMI)
Medium into a 50 mL centrifuge tube. The bone marrow in
media was then triturated with an 18-gauge needle until a
single cell suspension was obtained, followed by centrifugation
at 1,200×g for 5 min. The supernatant was carefully removed,
and cells were resuspended in 4 mL of RBC lysis buﬀer (0.15
M NH4Cl, 10 mM KHCO3, and 0.1 mM Na4EDTA), followed
by swirling by hand for 3 min. 6 mL of RPMI media was then
added, followed by centrifugation at 1200×g for 5 min. The
supernatant was aspirated oﬀ, and the cells were resuspended
in diﬀerentiation media (RPMI supplemented with 10% fetal
3853

https://dx.doi.org/10.1021/acsomega.0c05632
ACS Omega 2021, 6, 3847−3857

ACS Omega

http://pubs.acs.org/journal/acsodf

aspirated oﬀ and 100 μL of Optimem was added, followed by
20 μL of alamar blue for the cell viability assay.
Cell Viability Assay. For cytotoxicity assays, the cell media
from each well of a 96-well plate were exchanged for 100 μL of
Optimem (Invitrogen), followed by the addition of 20 μL of
alamar blue. Cells were then incubated for 35−45 min until a
uniform purple coloration was developed. The resulting
ﬂuorescence was measured using a Tecan 96-well plate reader
equipped with an excitation ﬁler set to 535 nm and the
emission ﬁlter set to 595 nm. All measurements were done in
quintuplicate (ﬁve diﬀerent wells), and at least three
independent experiments were carried out.
MEV Isolation. Completely diﬀerentiated macrophages
from day 8 were used to generate MEVs. The macrophage cell
media were aspirated oﬀ from the ﬂask containing macrophages, and the cells were ﬁrst washed with PBS. 3 mL of PBS
was further added to each ﬂask, and cells were detached by
scraping them, followed by resuspension in PBS. The cell
suspension from all ﬂasks was ﬁrst collected into a 50 mL tube,
and the total number of cells was counted using a
hematocytometer. The cell slurry collected in the previous
step was then centrifuged at 1200 rpm at 4 °C for 5 min, and
the obtained pellets were resuspended in 10 mL of PBS
supplemented with the protease inhibitor. To fragment the
cellular membrane and generate the vesicles, cells were then
subjected to a pressure of 300 psi for 5 min in a prechilled
nitrogen gas decompressor (Parr Instruments Company, IL,
USA) on ice. The pressure was rapidly released to generate
fragmentation resulting in vesicles. The fragmented cell
mixture including vesicles was centrifuged at 4000×g for 10
min at 4 °C. The pellet obtained was discarded, but the
supernatant was centrifuged at 10,000×g for 20 min at 4 °C.
The supernatant was again subjected to ultracentrifugation at
100,000×g for 60 min at 4 °C to pellet the remaining
nanovesicles. The pellet was washed ﬁve times with PBS before
being resuspended in 500 μL of the PBS buﬀer.
MEV Characterization. MEVs were generated by nitrogen
cavitation, followed by a series of centrifugation steps as
discussed above. The mean diameter, concentration, and zeta
potential of MEVs were determined via nanoparticle tracking
analysis (NTA) using a Nanosight 300 and a ZetaView PMX120. Similarly, MEV stability was determined using dynamic
light scattering (DLS). A ZetaPALS potential Analyzer
(Brookhaven Instruments) was used to obtain the DLS
measurements.
MEV Labeling. Cells were detached from the ﬂask and
counted and resuspended in 9.9 mL of PBS. 100 μL of 100
mM ﬂuorescein was added to the cell suspension so that the
ﬁnal concentration of ﬂuorescein becomes 1 mM in the cell
suspension. The cell solution was fragmented using nitrogen
cavitation, and the vesicle pellet was obtained. The pellet was
then washed with PBS to remove any unincorporated
ﬂuorescein inside the vesicle. Vesicles were then resuspended
in 1 mL of PBS and transferred to a clean ultracentrifuge
(UCF) tube where the vesicle suspension was diluted to 4 mL
in PBS. For the complete removal of the free dye, the diluted
vesicle suspension was recentrifuged at 100,000×g for 60 min
at 4 °C. The supernatant from centrifugation was discarded,
and the pellet was washed with 1 mL of the PBS buﬀer. 500 μL
of PBS was added to the UCF tube, and the pellet was
resuspended by pipetting several times. DiI was then added to
the vesicle resuspension such that the ﬁnal concentration of the
dye becomes 2 μM and left to incubate for 30 min at 37 °C.
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DiI is a lipophilic dye which gets incorporated into the lipid
bilayer of the vesicle. The free dye molecules were separated
from the ﬂuorescently labeled vesicles using a size exclusion
spin column (PD MidiTrap column). The column was
equilibrated ﬁrst by running 15 mL of PBS through the
column and the column was centrifuged at 1000g for 2 min to
remove any remaining PBS from the column. Then, 500 μL of
the vesicle solution was added carefully onto the center of the
column from the top and centrifuged at 1000g for 2 min to
obtain DiI-labeled vesicles loaded with ﬂuorescein.
MEV Imaging. DiI or ﬂuorescein-labeled vesicles were
generated as discussed previously and deposited onto a glass
bottom dish before imaging them using ﬂuorescence
microscopy. DiI-labeled vesicles were imaged using a 532 nm
laser of a 1.9 mW power with a gain of 990 and an exposure
time of 200 ms. Similarly, ﬂuorescein-loaded vesicles were
imaged using a 488 nm laser of a 0.8 mW power with a gain of
990 and an exposure time of 200 ms.
Confocal Imaging. A Nikon A1R laser scanning confocal
microscope equipped with a 60× oil objective was used for
confocal imaging of macrophages that had taken up dyelabeled vesicles. Thus, the obtained images were analyzed with
Nikon image processing software.59
MEV Uptake. 100 million M1 and 110 million M2
macrophages were used to prepare M1EVs and M2EVs,
respectively, for the study of MEV uptake by M1 or M2
macrophages. MEVs were generated and labeled with DiI as
mentioned previously. From total 500 μL of each vesicle
suspension, 50 μL of DiI-labeled vesicles was then added
separately to each glass bottom dish containing 90,000 M1 or
M2 macrophages. Imaging was done at 0.5, 1, 1.5, and 2 h
using a ﬂuorescence microscope equipped with a 20× objective
with an exposure time of 32 ms. The macrophage media with
ﬂuorescently labeled vesicles were ﬁrst removed, and the cells
were washed twice with 1 mL of L-15 prior to the addition of 1
mL of L-15 to the cells for imaging.
Cisplatin-Loaded MEVs. 100 million M0, M1, or M2 cells
were used to generate macrophage-derived, cisplatin-loaded
vesicles and deliver them to A549 cells. Macrophage media
were ﬁrst aspirated oﬀ, and 3 mL of PBS was added to each
ﬂask prior to scraping them. The cell solution was collected
into a 50 mL centrifuge tube, and the number of cells was
determined using a hematocytometer. The cell solution was
pelleted at 2000×g for 2 min at 4 °C. The supernatant was
discarded, and cells were resuspended in 8 mL of 8.33 mM
cisplatin solution made in PBS with 1 tablet of the protease
inhibitor. The cell solution was nitrogen-cavitated using a
prechilled nitrogen decompressor on ice at 300 psi for 5 min.
The cell lysate obtained was centrifuged at 4000×g for 10 min
at 4 °C. The pellet thus obtained was discarded, and the
obtained supernatant was centrifuged at 10,000×g for 20 min
at 4 °C. The supernatant obtained was again subjected to
ultracentrifugation at 100,000×g for 60 min at 4 °C to collect
the pellet containing cisplatin-loaded nanovesicles. This ﬁnal
pellet was ﬁrst washed with 1 mL of PBS twice and
resuspended in 750 μL of PBS. Empty vesicles were generated
using the same procedure discussed above but in the absence
of cisplatin.
Cisplatin Concentration in MEVs. The concentration of
cisplatin loaded in vesicles was determined using inductively
coupled plasma−optical emission spectrometry (ICP−OES).36
Cisplatin-loaded MEVs were ﬁrst treated with 1% Triton X100 to dissolve the lipid bilayer, followed by 70% nitric acid
3854

https://dx.doi.org/10.1021/acsomega.0c05632
ACS Omega 2021, 6, 3847−3857

ACS Omega

http://pubs.acs.org/journal/acsodf

Article

were considered statistically signiﬁcant at p-values less than or
equal to 0.01.

treatment to release platinum from cisplatin. The resulting
solution was further incubated on a heat block at 60 °C for 2 h,
followed by dilution to 5 mL, such that the ﬁnal nitric acid
concentration was 10% for analysis using ICP−OES. A
standard curve using platinum standards in 10% nitric acid
solution was used to determine the concentration. Ytterbium
was used as an internal standard to compensate for the internal
drift of the instrument. We have previously shown that vesicles
generated by nitrogen cavitation are stable with no apparent
cisplatin leakage for 72 h.36
Cytokine Analysis. MEVs were generated as described
before. M1EVs were generated from 100 million M1
macrophages and resuspended in 500 μL of PBS. The number
of vesicles present in the resuspension was determined using
NTA. 5.49 × 109 M1EVs were added into each well of a 24well plate containing 1 million M0 and M2 macrophages in
950 μL of replating media. The plate was left to incubate at 37
°C for 24 h. After 24 h of incubation, MCM were collected in
an Eppendorf tube (1 mL) and later used for pro-inﬂammatory
cytokine analysis. M2EVs were generated as before using M2
macrophages. 7.6 × 109 M2EVs were added to each well
containing M0 and M1 macrophages. The plate was left to
incubate at 37 °C for 24 h before collecting the media for
cytokine analysis. We performed a mouse pro-inﬂammatory
sevenplex assay following the manufacturer’s protocol. Brieﬂy,
25 μL of calibrators and MCM were added to each well of a
capture antibody-precoated MSD well plate. The plate was
then allowed to incubate for an hour, and the detection
antibody was added into each well of the MSD. After
vigorously shaking the plate for an hour, it was then washed
with 0.5% tween PBS. The Read buﬀer was ﬁnally added to
each well and analyzed on the MESO SECTOR imager from
Meso Scale Discovery. Standard curves were obtained by
ﬁtting the electrochemiluminescence signal from calibrators
using Meso Scale Delivery Workbench analysis software.
In Vivo Delivery. A549 cells (1 × 106) were injected
subcutaneously into the interscapular region of 6-week-old
athymic nude mice. The mice were monitored until palpable
xenograft tumors developed greater than 200 mm3. M1EVs
were generated using 100 million M1 macrophages by the
procedure mentioned above. A NanoSight 300 multiple
particle tracking system was used to determine the mean
diameter and the concentration of MEVs. M1EVs were then
labeled with the DiR near-infrared ﬂuorescent dye. Brieﬂy, 1
μL of 1 mM DiR was added to 199 μL of the vesicle
resuspension so that the ﬁnal concentration of DiR in the
vesicle resuspension was 5 μM. DiR-labeled vesicles were
separated from free DiR using a size exclusion PD MidiTrap
column equilibrated with PBS. 100 μL of DiR-labeled M1EVs
was then injected into the lateral tail vein of tumor-bearing
mice. Isoﬂurane gas was used to anesthetize mice for imaging
72 h post injection using an IVIS Spectrum In Vivo Imaging
System (PerkinElmer) controlled with LivingImage software
(PerkinElmer). Epiﬂuorescence images were obtained using
710 nm excitation and 760 nm emission ﬁlters, f/stop number
4 and binning factor 4, with a 35 s exposure.
Statistical Analysis. Statistical analyses were performed
using Origin 2018. All data were expressed as the mean ±
standard error of the mean (SEM). At least three independent
biological replicate experiments were performed for each
condition (n ≥ 3). The two-sample t-test or ANOVA with post
hoc Tukey’s HSD test was done when appropriate and results
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